Apollo Global in talks to acquire J&J’s DePuy Synthes orthopedics unit for $20 billion
Johnson & Johnson is in negotiations to sell its DePuy Synthes orthopedics unit, which generated $9.3 billion in sales last year, to Apollo Global Management for approximately $20 billion. The talks, reported by Bloomberg and the Wall Street Journal, could conclude within weeks but may collapse or see another bidder emerge. J&J may also spin off the business. The deal would be Apollo’s largest healthcare investment.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
J&J in talks to sell DePuy Synthes orthopedics unit to Apollo for $20 billion
Johnson & Johnson is in talks to sell its orthopedics unit, DePuy Synthes, to Apollo Global Management for close to $20 billion, according to Bloomberg. The unit, which makes hip and knee replacement devices, generated $9.3 billion in sales last year. Bloomberg reported that a deal could come together within weeks, though negotiations may collapse or a competing bidder could emerge. J&J could also opt to spin off the business as a publicly traded company instead of pursuing a sale, according to The Wall Street Journal. DePuy Synthes has drawn interest from several private equity firms. J&J announced plans last October to separate the unit, aiming to focus on higher-growth segments. CFO Joseph Wolk stated in July that the company is weighing all separation options to create shareholder value, with a mid-2027 separation timeline still intact. If the Apollo deal closes, it would represent the private equity firm's largest investment in healthcare. Representatives for Apollo and J&J declined to comment.
Read sourceJ&J in Talks to Sell Hips-and-Knees Business to Apollo for $20 Billion
Johnson & Johnson (J&J) is in talks to sell its hips-and-knees orthopedics business to private equity firm Apollo Global Management for approximately $20 billion, according to reports from the Wall Street Journal and Bloomberg News. The potential deal, which would involve J&J's DePuy Synthes orthopedics unit, has been reported by multiple financial news outlets. Following the news, JNJ stock edged up in after-hours trading, as reported by Yahoo Finance. The acquisition would represent a significant divestiture for J&J as it focuses on its core pharmaceutical and medical device businesses. Apollo Global is said to be in advanced discussions, though the deal is not yet finalized and could still fall through. The reports attribute the information to sources familiar with the matter.
Read sourceJ&J in Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion
Johnson & Johnson (J&J) is reportedly in negotiations to sell its hips-and-knees orthopedic business to private equity firm Apollo Global Management for approximately $20 billion. The deal, if completed, would represent a significant divestiture for J&J as it focuses on higher-growth areas like medical devices and pharmaceuticals. The information comes from a Yahoo Finance article summarizing the report, which cites sources familiar with the matter. The sale price and the identity of the buyer are central to the report, though the talks are ongoing and may not result in a finalized agreement.
Show 2 older updatesHide older updates
J&J in Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion
Johnson & Johnson (J&J) is reportedly in negotiations to sell its hips-and-knees medical device business to private equity firm Apollo Global Management for approximately $20 billion. The information comes from a report by Yahoo Finance, citing sources familiar with the matter. The potential deal would involve J&J divesting a significant part of its orthopedics portfolio, which focuses on hip and knee replacement products. The sale price of $20 billion reflects the value of this business unit. The talks are ongoing, and no final agreement has been reached, meaning the transaction could still fall through or change in terms. This move is part of J&J's broader strategy to streamline its operations and focus on higher-growth areas, such as pharmaceuticals and medical devices for other specialties. Apollo, a major investment firm, would acquire the business to expand its healthcare holdings.
Apollo Global in Talks to Acquire Johnson & Johnson's Orthopedics Unit for $20 Billion
Bloomberg reports that Apollo Global Management Inc. is in discussions to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, according to people familiar with the matter. The talks value the unit at close to $20 billion. An agreement could be reached within several weeks, but the talks could still end without one, or another bidder could emerge. J&J could also decide to spin off the business as a publicly traded company. J&J announced plans last October to separate its orthopedics business, and CFO Joseph Wolk said in July that the company continues to evaluate all separation options and is on track for a mid-2027 separation. The unit generated $9.3 billion in sales last year. Bloomberg Intelligence's Matt Henriksson estimated the business could be valued at $28 billion including debt. Acquiring DePuy Synthes would allow Apollo to put a large amount of money to work in a stable asset and would be its biggest bet yet on healthcare. J&J shares were little changed at $265.58, while Apollo shares rose 0.8% to $128.98.
Read source